Your session is about to expire
← Back to Search
LITT + Pembrolizumab for Brain Cancer (TORCH Trial)
TORCH Trial Summary
This trial is testing a new cancer treatment combining two existing treatments. The goal is to see if the combination can help people with brain cancer who have already tried other treatments.
TORCH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TORCH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have an ongoing hepatitis B or hepatitis C infection.You have a weakened immune system or are taking medications that lower your body's immune response.You have an ongoing serious illness or infection, heart problems, uncontrolled high blood pressure, or mental health issues that may make it hard for you to follow the study rules.You had lung inflammation in the last 3 years.You are eligible to receive pembrolizumab treatment.You have small metastatic lesions in your body that are either growing or new. You have five or fewer of these lesions, and they can be reached with a laser probe. You are able to have MRI scans and have had a contrast-enhanced MRI of the brain within 30 days before joining the study.You have a known history of HIV.You have been diagnosed with a specific type of cancer that can be treated with an immune-checkpoint inhibitor approved by the FDA.You have had previous radiation treatment for at least one metastatic lesion, and a specialist needs to review your scan before you can join the study.Your Karnofsky Performance Status (KPS) score is 70 or higher.You have a current or recent case of tuberculosis.You are taking a low dose of steroids (like dexamethasone) at the time you join the study.You have had a serious autoimmune disease that needed strong medicine in the last 2 years.Your bone marrow and organs need to be working properly, with specific levels of white blood cells, platelets, hemoglobin, and certain blood chemistry values.
- Group 1: Patients with Recurrent Brain Metastes
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree is the combination of LITT and Pembrolizumab potentially risky?
"Due to the limited data available on its safety and efficacy, our team at Power gave LITT + Pembrolizumab a score of 1."
How many participants is this clinical experiment enlisting?
"Affirmative. Clinicaltrials.gov's records demonstrate that this research project, which was initially launched on January 10th 2020, is actively recruiting participants. This study requires 16 patients to be enrolled from 2 distinct sites."
What other investigations have explored the dynamics of LITT and Pembrolizumab?
"Currently, 961 trials utilizing LITT + Pembrolizumab are underway with 122 in Phase 3. Although several of these research studies are based out of Houston, Texas, there is a total of 35731 sites all around the world conducting this trial."
Who is eligible to participate in this research endeavor?
"To be considered for this trial, applicants must have been diagnosed with melanoma and must fall between the ages of 18 to 100. A total of 16 participants are needed."
Are there vacancies in this medical trial for prospective participants?
"Affirmative. Per the data available on clinicaltrials.gov, this investigation is currently recruiting participants as of August 22nd 2022. This trial was initially posted on October 1st 2020 and requires 16 individuals from 2 separate sites to take part in the research."
Does the trial accept geriatric participants?
"This medical trial is seeking participants aged 18 to 100 years old."
What kind of symptoms does the combination of LITT and Pembrolizumab aim to reduce?
"Patients with malignant neoplasms are commonly treated with a combination of LITT and Pembrolizumab. This therapy is also beneficial for individuals suffering from unresectable melanoma, microsatellite instability high, or chemotherapy-induced progression."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger